-- Anteris Technologies（ASX：AVR）週四向澳洲證券交易所提交的文件顯示，該公司已通知v2vmedtech，將根據雙方於2023年4月18日簽署的出資及股權購買協議，停止向v2vmedtech提供額外的研發出資，並需向v2vmedtech支付40萬澳元的違約金。 該公司表示，發出通知後，不再有義務提供額外的研發出資。 v2vmedtech的初始股東有權選擇以下兩種方式之一：以相當於其迄今為止出資總額的價格收購該公司在v2vmedtech的全部股權；或將該公司的股權比例降低至上限規定的少數股權比例。 文件補充道，v2vmedtech尚未告知該公司其計劃採取哪種方案。 該公司還表示，雙方之間的研發協議將在支付40萬澳元違約金後終止。該公司預計，終止協議不會對其財務狀況或流動性產生重大不利影響。 該公司股價在最近的周四交易中上漲了3%。
Related Articles
Asia
Sanhua Intelligent Controls Q1 Profit Up 3%; Shares Rise 5%
Zhejiang Sanhua Intelligent Controls (SHE:002050) posted first-quarter attributable net profit of 927.6 million yuan, up 2.7% from 903.4 million yuan the previous year.Earnings per share declined to 0.22 yuan from 0.24 yuan, according to a Thursday filing with the Shenzhen bourse.Operating revenue climbed 1.4% year over year to 7.77 billion yuan from 7.67 billion yuan.Shares of the refrigeration and air-conditioning components maker were up 5% in recent trade.
$SHE:002050
Asia
Singapore's Total Employment Expands in Q1
Singapore's total employment grew by 5,000 during the first quarter of the year, compared to 2,300 a year earlier, marking the 18th consecutive quarter of job growth, according to preliminary data from the Ministry of Manpower released Thursday.Despite the year-on-year growth, employment was down from the 17,700 growth in the previous quarter, mainly due to broad-based weakening in the labor market.Overall, unemployment rates edged up to 2.1% in March, compared to 2.0% in December 2025.Retrenchments remained low at 1.5 per 1,000 employees in Q1, unchanged from Q4, 2025.The ministry expects labor market to remain tight and expand in the second quarter. However, the share of firms expecting to hire in the next three months fell to 44.6% in March, compared to 54.6% in February.
$^STI
Asia
Clarity Pharmaceuticals to Start Registrational Phase 3 Trial in Neuroendocrine Tumors After US FDA Meeting
Clarity Pharmaceuticals (ASX:CU6) will start a registrational phase 3 trial of copper-64-SARTATE in neuroendocrine tumors, following a successful end-of-phase meeting with the US Food and Drug Administration (FDA), according to a Thursday Australian bourse filing.The company plans to recruit around 70 participants for the trial.Clarity is also conducting recruitment for its registrational phase 3 positron emission tomography imaging trial of participants with high-risk prostate cancer prior to radical prostatectomy using copper-64-SAR-bisPSMA in the US and Australia, per the filing. It plans to recruit around 383 participants.The trial will assess the diagnostic performance of copper-64-SAR-bisPSMA positron emission tomography in detecting prostate cancer within the pelvic lymph nodes, the filing said.Clarity Pharmaceuticals' shares fell nearly 2% in recent trading on Thursday.
$ASX:CU6